Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11543280 | 0.91 | VCAM1 (0.53) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL11540783 | 0.90 | VCAM1 (0.52) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL14882355 | 0.90 | VCAM1 (0.64) | VCAM1POLBMAPTALDH1A1HPGD | |
| SCHEMBL574190 | 0.89 | VCAM1 (0.51) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL11541635 | 0.89 | MAPT (0.55) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL15677242 | 0.88 | CA2 (0.49) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL573640 | 0.88 | KDM4E (0.58) | VCAM1POLBCA2CA1CA9 | |
| SCHEMBL11840209 | 0.87 | CA2 (0.50) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL573529 | 0.87 | VCAM1 (0.51) | VCAM1POLBMAPTCA2CA1 | |
| SCHEMBL11540771 | 0.87 | POLB (0.61) | VCAM1POLBMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20140128469-A1 | DEUTERATED N-BUTYL BUMETANIDE | CONCERT PHARMACEUTICALS INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128469-A1 | DEUTERATED N-BUTYL BUMETANIDE | CONCERT PHARMACEUTICALS INC. (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2598478-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013059648-A1 | 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012154728-A1 | DEUTERATED N-BUTYL BUMETANIDE | CONCERT PHARMACEUTICALS INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154728-A1 | DEUTERATED N-BUTYL BUMETANIDE | CONCERT PHARMACEUTICALS INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012018635-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012018635-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128469-A1 | DEUTERATED N-BUTYL BUMETANIDE | ABCB11, SLC10A1, CYP11B1 | VCAM1 3016/4885POLB 2585/4885MAPT 2304/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | VCAM1 1370/4885POLB 3419/4885MAPT 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.